Spotlight on Nephrology

Credits: 0.25 CME
Pathways to Improved Care in FSGS and IgAN – Highlights in FSGS and IgAN
Jai Radhakrishnan, MD, MS, FASN
Academy for Continued Healthcare Learning

Pathways to Improved Care in FSGS and IgAN – Highlights in FSGS and IgAN

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 31, 2022
Expires: May 31, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Dr. Jai Radhakrishnan explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) from a recent nephrology meeting in this brief interview-style video. Dr. Radhakrishnan discusses emerging data on the pathophysiology and treatment of FSGS and IgAN in addition to the clinical implications of these advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are limited therapies and the management of FSGS and IgAN is challenging. There are new potential therapeutic targets and a number of ongoing clinical trials in FSGS and IgAN. This education brings clinicians up-to-date on the latest data on these progressive kidney diseases.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents under investigation for FSGS and IgAN.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 31, 2022
Expires: May 31, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Dr. Jai Radhakrishnan explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) from a recent nephrology meeting in this brief interview-style video. Dr. Radhakrishnan discusses emerging data on the pathophysiology and treatment of FSGS and IgAN in addition to the clinical implications of these advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are limited therapies and the management of FSGS and IgAN is challenging. There are new potential therapeutic targets and a number of ongoing clinical trials in FSGS and IgAN. This education brings clinicians up-to-date on the latest data on these progressive kidney diseases.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents under investigation for FSGS and IgAN.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Nephrology Presentations

0.5 CME
RMEI Medical Education, LLC
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant

An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: June 7, 2022
Expires: June 6, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
  • Employ established criteria to diagnose kidney transplant recipients with chronic active AMR

Activity Description

This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.

Faculty

Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.25 CME
Academy for Continued Healthcare Learning
Pathways to Improved Care in FSGS and IgAN – Highlights in FSGS and IgAN

Pathways to Improved Care in FSGS and IgAN – Highlights in FSGS and IgAN

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 31, 2022
Expires: May 31, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Dr. Jai Radhakrishnan explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) from a recent nephrology meeting in this brief interview-style video. Dr. Radhakrishnan discusses emerging data on the pathophysiology and treatment of FSGS and IgAN in addition to the clinical implications of these advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are limited therapies and the management of FSGS and IgAN is challenging. There are new potential therapeutic targets and a number of ongoing clinical trials in FSGS and IgAN. This education brings clinicians up-to-date on the latest data on these progressive kidney diseases.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents under investigation for FSGS and IgAN.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 31, 2022
Expires: May 31, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Dr. Jai Radhakrishnan explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) from a recent nephrology meeting in this brief interview-style video. Dr. Radhakrishnan discusses emerging data on the pathophysiology and treatment of FSGS and IgAN in addition to the clinical implications of these advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are limited therapies and the management of FSGS and IgAN is challenging. There are new potential therapeutic targets and a number of ongoing clinical trials in FSGS and IgAN. This education brings clinicians up-to-date on the latest data on these progressive kidney diseases.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents under investigation for FSGS and IgAN.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

0.25 CME
Academy for Continued Healthcare Learning
Pathways to Improved Care in FSGS and IgAN – Latest Data in FSGS and IgAN

Pathways to Improved Care in FSGS and IgAN – Latest Data in FSGS and IgAN

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 13, 2022
Expires: April 13, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA Nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Richard Lafayette, MD
Stanford Department of Medicine, Nephrology
Stanford, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Richard Lafayette, MD (Faculty)
Advisor or Review Panel member: Calliditas, Chinook, Novartis, Otsuka/Visterra, Travere, Vera
Consultant (Occasional): Novartis, Omeros
Grant/Research Support recipient: Calliditas, Chinook, Omeros, Otsuka/Visterra, Travere, Vera

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 13, 2022
Expires: April 13, 2023
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists, and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA Nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Richard Lafayette, explores clinical trial data coming out of a recent nephrology meeting, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Lafayette will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Richard Lafayette, MD
Stanford Department of Medicine, Nephrology
Stanford, CA

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Richard Lafayette, MD (Faculty)
Advisor or Review Panel member: Calliditas, Chinook, Novartis, Otsuka/Visterra, Travere, Vera
Consultant (Occasional): Novartis, Omeros
Grant/Research Support recipient: Calliditas, Chinook, Omeros, Otsuka/Visterra, Travere, Vera

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Jai Radhakrishnan, MD, MS, FASN
0.25 CME
Academy for Continued Healthcare Learning
Pathways to Improved Care in FSGS and IgAN – Highlights from Kidney Week

Pathways to Improved Care in FSGS and IgAN – Highlights from Kidney Week

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 9, 2021
Expires: November 9, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Jai Radhakrishnan, explores clinical trial data coming out of ASN 2021, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

This coverage is not sanctioned by the ASN Kidney Week conference organizers and is not an official part of the conference proceedings.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 9, 2021
Expires: November 9, 2022
15 minutes to complete

Accredited By

Target Audience

This activity is intended for nephrologists and primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
  • Outline emerging therapies and pathways for FSGS and IgAN
  • Interpret clinical trial data and endpoints from clinical trials with emerging therapies

Activity Description

Expert faculty, Dr. Jai Radhakrishnan, explores clinical trial data coming out of ASN 2021, and provides learners with up-to-date knowledge on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). This brief interview-style video offers insights into the patient burden of chronic kidney disease, advances in understanding the pathophysiology, and emerging approaches to treatment for this patient population. Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

This coverage is not sanctioned by the ASN Kidney Week conference organizers and is not an official part of the conference proceedings.

Statement of Educational Need

Focal segmental glomerulosclerosis and IgAN are glomerular disorders that contribute to kidney failure and the need for dialysis and/or transplant. Although both are associated with kidney injury, they have different pathophysiologies, along with considerable disease heterogeneity. There are no currently approved therapies and the management of FSGS and IgAN is challenging. Recent research has identified potential therapeutic targets for individuals with these progressive kidney diseases and there are a number of ongoing clinical trials. This education brings clinicians up-to-date on potential treatment targets and agents in the pipeline for progressive kidney disease.

Agenda

Dr. Radhakrishnan will discuss current barriers, emerging evidence, and strategies to incorporate advances.

Faculty

Jai Radhakrishnan, MD, MS, FASN
Professor of Medicine
Columbia University Medical Center
Clinical Director, Nephrology Division
New York Presbyterian Hospital-Columbia
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:
Jai Radhakrishnan, MD, MS, FASN (Faculty)
Consultant (Occasional): Angion Biomedica, Aurinia Pharmaceuticals, GlaxoSmithKline, Equillium Bio, Reistone Biopharma, Sanofi Genzyme, Travere Therapeutics, Inc.
Grant/Research Support: Travere Therapeutics, Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Travere Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.